| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/FEMSPD/FTW075 |
| P698 | PubMed publication ID | 27604468 |
| P50 | author | Marta Carretero | Q42828379 |
| Rogelio Hernández-Pando | Q59978499 | ||
| Octavio Ramos-Espinosa | Q86826096 | ||
| P2093 | author name string | Jorge Barrios-Payán | |
| Marcela Del Río | |||
| Fernando López-Casillas | |||
| Brenda Marquina-Castillo | |||
| Alejandro Francisco-Cruz | |||
| Dulce Mata-Espinosa | |||
| Sujhey Hernández-Bazán | |||
| P2860 | cites work | The NF-kappa B and I kappa B proteins: new discoveries and insights | Q24313579 |
| LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells | Q24675869 | ||
| Antimicrobial peptides of multicellular organisms | Q28131811 | ||
| Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 | ||
| Defensins: antimicrobial peptides of innate immunity | Q28204453 | ||
| Gutless adenovirus: last-generation adenovirus for gene therapy | Q28277560 | ||
| Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models | Q28488709 | ||
| Immunogenicity and other problems associated with the use of biopharmaceuticals | Q33416851 | ||
| Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology | Q34006525 | ||
| The human beta-defensin-3, an antibacterial peptide with multiple biological functions | Q34566449 | ||
| How can immunology contribute to the control of tuberculosis? | Q34572120 | ||
| Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management | Q34648346 | ||
| Mechanisms of latency in Mycobacterium tuberculosis | Q34747144 | ||
| Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection | Q35211295 | ||
| Biology of adenovirus and its use as a vector for gene therapy | Q35989621 | ||
| Human beta-defensins | Q36482561 | ||
| Delivery of therapeutic proteins | Q37668486 | ||
| Innate immune recognition of Mycobacterium tuberculosis | Q37878291 | ||
| Adjunct immunotherapies for tuberculosis | Q37998000 | ||
| Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers. | Q38148589 | ||
| Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis | Q39607841 | ||
| 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity | Q39929520 | ||
| Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. | Q40259693 | ||
| Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. | Q40321158 | ||
| Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. | Q40425524 | ||
| A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides | Q40509451 | ||
| Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis | Q40565805 | ||
| A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. | Q40675926 | ||
| Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. | Q40692879 | ||
| The pathogenesis of tuberculosis | Q41199562 | ||
| Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword? | Q42236324 | ||
| Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis | Q43772784 | ||
| Development of replication-defective herpes simplex virus vectors | Q44309006 | ||
| Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic | Q44440459 | ||
| Therapeutic Effect of Recombinant Adenovirus Encoding Interferon-γ in a Murine Model of Progressive Pulmonary Tuberculosis | Q45864483 | ||
| Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis. | Q54419473 | ||
| Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection | Q56485907 | ||
| Pneumococcal Adaptive Responses to Changing Host Environments | Q57983128 | ||
| Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis | Q58826831 | ||
| P433 | issue | 7 | |
| P921 | main subject | gene therapy | Q213901 |
| antimicrobial peptide | Q1201508 | ||
| P577 | publication date | 2016-09-07 | |
| P1433 | published in | Pathogens and disease | Q27724629 |
| P1476 | title | Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis | |
| P478 | volume | 74 |
| Q50259871 | Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis |
| Q47093744 | Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis |
| Q40045291 | Opening Pandora's Box: Mechanisms of Mycobacterium tuberculosis Resuscitation |
| Q47130424 | The Role of Mast Cells in Tuberculosis: Orchestrating Innate Immune Crosstalk? |
Search more.